Isabelle Schrauwen1,2,3, Hanne Valgaeren1, Laura Tomas-Roca4,5, Manou Sommen1, Umut Altunoglu6, Hannie Kremer4,5,7, Guy Van Camp8, Hans van Bokhoven9,10, Mieke Wesdorp5,7,11, Matthias Beyens1, Erik Fransen1, Abdul Nasir12, Geert Vandeweyer1, Anne Schepers1, Malika Rahmoun4,5, Ellen van Beusekom4, Matt J Huentelman2, Erwin Offeciers13, Ingeborg Dhooghe14, Alex Huber15, Paul Van de Heyning16, Diego Zanetti17, Els M R De Leenheer7,14, Christian Gilissen4, Alexander Hoischen4,7,18, Cor W Cremers7, Berit Verbist19,20, Arjan P M de Brouwer4,5, George W Padberg5,21, Ronald Pennings5,7, Hülya Kayserili22. 1. Center of Medical Genetics, University of Antwerp & Antwerp University Hospital, Antwerp, Belgium. 2. Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA. 3. Center for Statistical Genetics, Molecular and Human Genetics Department, Baylor College of Medicine, Houston, TX, USA. 4. Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands. 5. Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands. 6. Medical Genetics Department, Istanbul Medical Faculty, Istanbul University, İstanbul, Turkey. 7. Department of Otorhinolaryngology, Hearing & Genes, Radboud University Medical Center, Nijmegen, The Netherlands. 8. Center of Medical Genetics, University of Antwerp & Antwerp University Hospital, Antwerp, Belgium. guy.vancamp@uantwerpen.be. 9. Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands. Hans.vanBokhoven@radboudumc.nl. 10. Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands. Hans.vanBokhoven@radboudumc.nl. 11. Radboud Institute of Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. 12. Synthetic Protein Engineering Lab (SPEL), Department of Molecular Science and Technology, Ajou University, Suwon, South Korea. 13. European Institute for ORL, St-Augustinus Hospital Antwerp, Antwerp, Belgium. 14. Department of Otolaryngology, Ghent University Hospital, Ghent, Belgium. 15. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland. 16. Department of ORL and Head and Neck Surgery, Antwerp University Hospital, University of Antwerp, Edegem, Belgium. 17. Dept. of Clinical Sciences and Community Health, Audiology Unit, University of Milan, I.R.C.C.S. Fondazione "Cà Granda", Osp.le Maggiore Policlinico, Milano, Italy. 18. Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands. 19. Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. 20. Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. 21. Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands. 22. Medical Genetics Department, Koç University School of Medicine (KUSOM), İstanbul, Turkey.
Abstract
PURPOSE: To characterize new molecular factors implicated in a hereditary congenital facial paresis (HCFP) family and otosclerosis. METHODS: We performed exome sequencing in a four-generation family presenting nonprogressive HCFP and mixed hearing loss (HL). MEPE was analyzed using either Sanger sequencing or molecular inversion probes combined with massive parallel sequencing in 89 otosclerosis families, 1604 unrelated affected subjects, and 1538 unscreened controls. RESULTS: Exome sequencing in the HCFP family led to the identification of a rare segregating heterozygous frameshift variant p.(Gln425Lysfs*38) in MEPE. As the HL phenotype in this family resembled otosclerosis, we performed variant burden and variance components analyses in a large otosclerosis cohort and demonstrated that nonsense and frameshift MEPE variants were significantly enriched in affected subjects (p = 0.0006-0.0060). CONCLUSION: MEPE exerts its function in bone homeostasis by two domains, an RGD and an acidic serine aspartate-rich MEPE-associated (ASARM) motif inhibiting respectively bone resorption and mineralization. All variants associated with otosclerosis are predicted to result in nonsense mediated decay or an ASARM-and-RGD-truncated MEPE. The HCFP variant is predicted to produce an ASARM-truncated MEPE with an intact RGD motif. This difference in effect on the protein corresponds with the presumed pathophysiology of both diseases, and provides a plausible molecular explanation for the distinct phenotypic outcome.
PURPOSE: To characterize new molecular factors implicated in a hereditary congenital facial paresis (HCFP) family and otosclerosis. METHODS: We performed exome sequencing in a four-generation family presenting nonprogressive HCFP and mixed hearing loss (HL). MEPE was analyzed using either Sanger sequencing or molecular inversion probes combined with massive parallel sequencing in 89 otosclerosis families, 1604 unrelated affected subjects, and 1538 unscreened controls. RESULTS: Exome sequencing in the HCFP family led to the identification of a rare segregating heterozygous frameshift variant p.(Gln425Lysfs*38) in MEPE. As the HL phenotype in this family resembled otosclerosis, we performed variant burden and variance components analyses in a large otosclerosis cohort and demonstrated that nonsense and frameshift MEPE variants were significantly enriched in affected subjects (p = 0.0006-0.0060). CONCLUSION: MEPE exerts its function in bone homeostasis by two domains, an RGD and an acidic serine aspartate-rich MEPE-associated (ASARM) motif inhibiting respectively bone resorption and mineralization. All variants associated with otosclerosis are predicted to result in nonsense mediated decay or an ASARM-and-RGD-truncated MEPE. The HCFP variant is predicted to produce an ASARM-truncated MEPE with an intact RGD motif. This difference in effect on the protein corresponds with the presumed pathophysiology of both diseases, and provides a plausible molecular explanation for the distinct phenotypic outcome.
Authors: Joanna L Ziff; Michael Crompton; Harry R F Powell; Jeremy A Lavy; Christopher P Aldren; Karen P Steel; Shakeel R Saeed; Sally J Dawson Journal: Hum Mol Genet Date: 2016-04-07 Impact factor: 6.150
Authors: Chike Cao; Aaron B Oswald; Brian A Fabella; Yinshi Ren; Ramona Rodriguiz; George Trainor; Matthew B Greenblatt; Matthew J Hilton; Geoffrey S Pitt Journal: Bone Date: 2019-05-20 Impact factor: 4.398
Authors: Allan Thomas Højland; Lisse J M Tavernier; Guy Van Camp; Erik Fransen; Isabelle Schrauwen; Manou Sommen; Vedat Topsakal; Isabelle Schatteman; Ingeborg Dhooge; Alex Huber; Diego Zanetti; Henricus P M Kunst; Alexander Hoischen; Michael B Petersen Journal: Hum Genet Date: 2021-08-19 Impact factor: 4.132